Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002881|
Recruitment Status : Completed
First Posted : August 24, 2004
Last Update Posted : November 9, 2010
RATIONALE: Hormone therapy may be an effective treatment for prostate cancer.
PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: flutamide Drug: goserelin acetate Drug: leuprolide acetate Drug: suramin Drug: therapeutic hydrocortisone Procedure: orchiectomy||Phase 3|
OBJECTIVES: I. Compare time to progression and survival in patients with metastatic or recurrent adenocarcinoma of the prostate treated with orchiectomy or LHRH analogue (i.e. leuprolide or goserelin) plus flutamide with vs. without suramin and hydrocortisone. II. Compare these two treatments with respect to qualitative and quantitative toxic effects. III. Evaluate normalization of prostatic-specific antigen (PSA), duration of PSA response, and the use of PSA as a surrogate marker of tumor response in these patients. IV. Compare these two treatments with respect to quality of life and pain status.
OUTLINE: This is a randomized study. Patients are stratified by their choice of androgen suppression technique and by participating institution. Within 3 days after randomization, all patients receive daily flutamide. On day 4, patients undergo orchiectomy or begin monthly LHRH analogue therapy with leuprolide or goserelin. Patients randomized to receive suramin begin a 12-week course 8-25 days after orchiectomy/LHRH therapy. Hydrocortisone replacement therapy begins concomitantly with suramin and continues for at least 3 months after the completion of suramin treatment or until disease progression intervenes. Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 800-1,000 patients will be entered within 3.25 to 4.25 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||PHASE III TRIAL OF ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE + SURAMIN + HYDROCORTISONE VS ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE IN PATIENTS WITH METASTATIC PROSTATE CANCER|
|Study Start Date :||October 1996|
|Actual Primary Completion Date :||April 1998|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002881
|United States, District of Columbia|
|Walter Reed Army Medical Center|
|Washington, District of Columbia, United States, 20307-5000|
|Study Chair:||George Wilding, MD||University of Wisconsin, Madison|
|Study Chair:||Nancy A. Dawson, MD||Walter Reed Army Medical Center|
|Study Chair:||A. O. Sartor, MD||Louisiana State University Health Sciences Center in New Orleans|